BRISTOL OTC QUESTRAN 90% LABEL COMPLIANCE IN STUDY IS DIFFICULT TO EXTRAPOLATE TO REAL WORLD, FDA REVIEWER SAYS; ADVISORY CMTES. SPLIT ON OTC SUITABILITY
An "actual use" study of over-the-counter Questran (cholestyramine) showed that 90% of subjects complied with the label by consulting a physician before using the drug or by opting not to use the drug, Bristol-Myers Squibb reported at a May 13 joint meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees. The groups met to consider whether Questran and Questran Light Rx treatments for hypercholesterolemia are appropriate candidates for OTC marketing.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth